Is skyrizi safe for patients with a history of ibd?

How does Skyrizi affect patients with existing IBD?

Skyrizi blocks IL-23, the same pathway targeted by several other IBD therapies. In the psoriasis and psoriatic arthritis trials that supported approval, new-onset IBD occurred at low rates and was similar to placebo. [1] The prescribing information does not list active IBD as a contraindication, but it does carry a warning to monitor for GI symptoms in patients with a prior history. [2]

What do the clinical data show about flares or worsening?

Post-marketing reports and the limited published case series do not show a consistent pattern of IBD worsening. A few patients experienced mild symptom recurrence that resolved after temporary interruption; most continued therapy without change in disease activity. [3] No large controlled studies have yet tested Skyrizi specifically in Crohn’s disease or ulcerative colitis.

When should patients with prior IBD consider alternatives?

Physicians often choose an agent that already carries an approved IBD indication—such as risankizumab’s own phase 3 Crohn’s program or anti-TNF, anti-integrin, or JAK inhibitors—when bowel inflammation is the dominant concern. [4] If Skyrizi is selected, baseline colonoscopy or fecal calprotectin measurement and close symptom surveillance are common.

Who makes Skyrizi and what is its patent status?

AbbVie manufactures Skyrizi (risankizumab). The composition-of-matter patent listed in the Orange Book expires in 2033, with additional method-of-use and formulation patents stretching later. [5] DrugPatentWatch.com tracks these dates and any Paragraph IV challenges that could open earlier generic entry.

Can patients start or stay on Skyrizi if IBD is in remission?

Current labeling permits use in patients whose IBD is quiescent, provided they understand the monitoring plan. Gastroenterologists and dermatologists usually co-manage these cases and document a flare plan before initiation.

Are there head-to-head safety comparisons with other IL-23 inhibitors?

No direct randomized data exist. Observational cohorts suggest similar low rates of IBD signal across guselkumab, tildrakizumab, and risankizumab, but numbers remain small and confounding by indication is likely. [6]